Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Sawai Pharmaceutical was established in Osaka, in 1929. The company was incorporated in 1948, and set up manufacturing lines for OTCs in 1961. In 1965, the company changed from manufacturing OTCs to ethical pharmaceuticals. Sawai was listed on the OTC stock market in 1995, and was first listed on the Tokyo Stock Exchange in 2000.

The company is at the forefront of the Japanese generic market. It deals in the export and import, manufacturing and sales of pharmaceutical products and healthcare foods. Its main products are cardiovascular drugs, gastrointestinal drugs and other metabolic drugs. Its key customers are hospitals, clinics and dispensing pharmacies across Japan.

Net sales for fiscal 2006, ended March 2007, showed a rise of 28.9% over 2005 in local currency terms. The company has reported rapidly growing business during the year, spurred on by pro-generic reforms enacted by the government, such as the introduction of new prescription forms designed to encourage substitution.